secwatch / observer
8-K filed December 16, 2022, 6:59 PM ET ticker QNCX CIK 0001662774
regulatory confidence high sentiment negative materiality 0.80

Quince Therapeutics, Inc. (QNCX): Nasdaq/NYSE listing notice — Quince Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period.

Quince Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Quince Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange
nasdaq
Notice
deficiency notice
Deficiency
minimum bid price
Rules
5450(a)(1), 5810(c)(3)(A)
Exact text from the filing
December 13, 2022, Quince Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (
View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-307303
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.